BioCentury | Aug 5, 2020
Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

While most master protocols for COVID-19 have converged on an overlapping set of experimental therapies, the COVID R&D Alliance’s adaptive trial is kicking off with five therapeutic targets largely untouched in the indication. Three members...
BioCentury | Mar 22, 2019
Financial News

Spinal cord injury company NervGen raises $10M IPO

...Case Western Reserve University. Silver's team showed that protein tyrosine phosphatase receptor type S (PTPRS) inhibits nerve growth and identified a PTPRS...
...after SCI. NVG-291 is an analog of Case Western's PTPRS inhibitor. NervGen plans to investigate PTPRS...
BioCentury | Oct 31, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers The numbers of circulating hybrid leukocyte-epithelial cells expressing PTPRC and creatine kinase could help predict survival in pancreatic cancer. In 18 patients, high numbers of the hybrid cells expressing PTPRC and creatine...
BioCentury | Oct 31, 2018
Distillery Therapeutics

Neurology

INDICATION: Addiction In vitro and mouse studies identified an illudalic acid-based PTPRD inhibitor that could help treat cocaine addiction. In a mouse model of cocaine addiction, heterozygous knockout of PTPRD decreased cocaine self-administration compared with...
BioCentury | Oct 11, 2018
Distillery Therapeutics

Autoimmune disease

...INDICATION: Multiple sclerosis (MS) Mouse studies suggest PTPRS mimetics could help treat MS. In the experimental...
...In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, a small peptide mimetic of PTPRS...
...the second model, the peptide increased remyelination. Next steps could include optimizing the peptide. TARGET/MARKER/PATHWAY: Protein tyrosine phosphatase receptor type S (PTPRS)...
BioCentury | Jun 22, 2018
Targets & Mechanisms

T cell balancing act

Among the improvements to next-generation CAR T cell therapies is the need to optimize the ratios of the different T cell subsets. While CD8 + T cells have grabbed most of the attention, a study...
BioCentury | Jan 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jan 2, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy Non-immune cells engineered with synthetic circuits to produce cytotoxic output in response to tumor antigens could help treat cancer. The method involves engineering HEK cells or human mesenchymal stem cell (MSC) lines...
BioCentury | Dec 19, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes Patient sample and mouse studies suggest inhibiting PTPRG could help treat insulin resistance. In liver samples from patients with non-alcoholic fatty liver disease (NAFLD), high levels of PTPRG were associated with high activity...
BioCentury | Mar 24, 2017
Company News

Critical Path biomarker consortium

The Critical Path Institute launched a consortium that will aim to qualify biomarkers for Type I diabetes with FDA and EMA. The Leona M. and Harry B. Helmsley Charitable Trust, the Janssen Research & Development...
Items per page:
1 - 10 of 32